Axonics Inc
NASDAQ:AXNX
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
55.99
70.98
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one AXNX stock under the Base Case scenario is 33.81 USD. Compared to the current market price of 70.98 USD, Axonics Inc is Overvalued by 52%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Axonics Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for AXNX cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Axonics Inc
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Axonics Inc
Balance Sheet Decomposition
Axonics Inc
Current Assets | 525.9m |
Cash & Short-Term Investments | 345.2m |
Receivables | 62.6m |
Other Current Assets | 118m |
Non-Current Assets | 248.3m |
PP&E | 41.6m |
Intangibles | 183m |
Other Non-Current Assets | 23.7m |
Current Liabilities | 64.4m |
Accounts Payable | 20.1m |
Accrued Liabilities | 44.3m |
Non-Current Liabilities | 45.3m |
Other Non-Current Liabilities | 45.3m |
Earnings Waterfall
Axonics Inc
Revenue
|
431.9m
USD
|
Cost of Revenue
|
-101.1m
USD
|
Gross Profit
|
330.8m
USD
|
Operating Expenses
|
-338m
USD
|
Operating Income
|
-7.2m
USD
|
Other Expenses
|
1.6m
USD
|
Net Income
|
-5.7m
USD
|
Free Cash Flow Analysis
Axonics Inc
USD | |
Free Cash Flow | USD |
In the third quarter of 2023, Axonics delivered solid performance with total revenue rising to $93.1 million, a 32% increase over the same period last year. The growth was driven by a 30% rise in sacral neuromodulation (SNM) revenue to $73.9 million, even against a tough comparison from the previous year's third-quarter 42% growth spike, partially driven by high utilization at existing U.S. accounts and new competitive accounts. SNM sales surged nearly 40% internationally, thanks to the impact of a new direct sales force in Australia. Bulkamid revenue soared by 42% to $19.2 million, propelled by increasing reorders and the addition of new accounts. The company's gross margin improved to 74.2% from 72.8%, alongside robust profitability metrics, including $14 million of adjusted EBITDA and nearly $4 million in net income. Looking ahead, full-year revenue guidance has been lifted to $362 million, indicating a 32% growth from the previous year.
What is Earnings Call?
AXNX Profitability Score
Profitability Due Diligence
Axonics Inc's profitability score is 41/100. The higher the profitability score, the more profitable the company is.
Score
Axonics Inc's profitability score is 41/100. The higher the profitability score, the more profitable the company is.
AXNX Solvency Score
Solvency Due Diligence
Axonics Inc's solvency score is 69/100. The higher the solvency score, the more solvent the company is.
Score
Axonics Inc's solvency score is 69/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
AXNX Price Targets Summary
Axonics Inc
According to Wall Street analysts, the average 1-year price target for AXNX is 73.33 USD with a low forecast of 71.71 USD and a high forecast of 78.75 USD.
Dividends
Current shareholder yield for AXNX is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
AXNX Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Axonics, Inc. is a medical device company, which engages in developing and commercializing of novel implantable sacral neuromodulation (SNM) devices to treat patients with bladder and bowel dysfunction. The company is headquartered in Irvine, California and currently employs 517 full-time employees. The company went IPO on 2018-10-31. The company is engaged in developing and commercializing products for patients with bladder and bowel dysfunction. The bladder and bowel dysfunction includes implantable sacral neuromodulation (SNM) systems to treat urinary urge incontinence (UUI) and urinary urgency frequency (UUF), together referred to as overactive bladder (OAB), as well as fecal incontinence (FI), and non-obstructive urinary retention (UR), and a urethral bulking agent to treat female stress urinary incontinence (SUI). The company has designed and developed the rechargeable sacral neuromodulation (SNM) system (r-SNM System), which delivers mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company has two relating to its r-SNM System, a European study, RELAX-OAB, and a United States pivotal study, ARTISAN-SNM. The company offers urethral bulking agent, Bulkamid for stress urinary incontinence.
Contact
IPO
Employees
Officers
The intrinsic value of one AXNX stock under the Base Case scenario is 33.81 USD.
Compared to the current market price of 70.98 USD, Axonics Inc is Overvalued by 52%.